SCHEMBL2835784

SCHEMBL2835784

CNC(=O)c1c(-c2ccc(Cl)s2)oc2ccc(OC)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 6/20 0.48
KDM4E B2RXH2 11/20 0.46
ALDH1A1 P00352 11/20 0.46
HPGD P15428 10/20 0.46
HSD17B10 Q99714 5/20 0.46
LMNA P02545 3/20 0.46
TSHR P16473 1/20 0.46
SMN1; SMN2 Q16637 6/20 0.45
POLB P06746 1/20 0.45
NPC1 O15118 4/20 0.44
RAB9A P51151 3/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
MTNR1A P48039 1/20 0.42
MTNR1B P49286 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
TP53 P04637 2/20 0.42
HTT P42858 1/20 0.42
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2839629 0.88 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL2839623 0.82 KDM4E (0.49) GAAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2840167 0.81 KDM4E (0.62) GAAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2838934 0.80 ALDH1A1 (0.52) GAAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2840687 0.79 KDM4E (0.73) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL2843671 0.77 KDM4E (0.49) GAAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2844212 0.77 ANO1 (0.49) GAAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2834620 0.77 ANO1 (0.61) GAAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2840378 0.77 KDM4E (0.57) GAAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2839566 0.77 ANO1 (0.61) GAAKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4537315-B2 2010-09-01 JP claimed
US-7666863-B2 Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases VIROPHARMA INCORPORATED (US) 2010-02-23 US claimed
US-20070231318-A1 BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES SAHA ASHIS K 2007-10-04 US claimed
EP-1581207-A4 BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES VIROPHARMA INC (US) 2007-07-25 EP claimed
JP-2006510736-A 2006-03-30 JP claimed
EP-1581207-A2 BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES Viropharma Incorporated (US) 2005-10-05 EP claimed
US-20040162318-A1 Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases VIROPHARMA INCORPORATED 2004-08-19 US claimed
WO-2004041201-A2 BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES VIROPHARMA INCORPORATED (US) 2004-05-21 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070231318-A1 BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES BBOX1, HAVCR2, CYP2E1 GAA 735/4885KDM4E 2787/4885ALDH1A1 189/4885
US-20040162318-A1 Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases BBOX1, HAVCR2, CYP2E1 GAA 735/4885KDM4E 2787/4885ALDH1A1 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.